Renaissance Capital logo

VERA News

US IPO Weekly Recap: Postponements abound in a turbulent 5 IPO week

ZENV

The IPO market had a tumultuous week with five IPOs and three postponements: Brazilian customer service platform Zenvia (ZENV), mortgage insurance spinoff Enact Holdings (ACT), and hearing care services provider ...read more

Immunological disease biotech Vera Therapeutics prices IPO well below the range at $11

Vera Therapeutics logo

Vera Therapeutics, a Phase 2b biotech developing fusion proteins for immunological diseases, raised $48 million by offering 4.4 million shares at $11, below the range of $14 to $16. At pricing, the company commands a fully diluted market value of $244 million. ...read more

Immunological disease biotech Vera Therapeutics sets terms for $65 million IPO

Vera Therapeutics logo

Vera Therapeutics, a Phase 2b biotech developing fusion proteins for immunological diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $65 million by offering 4.4 million shares at a price range of $14...read more

US IPO Week Ahead: Mortgage insurance and cross-border e-commerce lead an 8 IPO week

ACT

Updated Monday, 5/10. Eight IPOs are slated to raise $1.6 billion in the week ahead, led by private mortgage insurance company Enact Holdings (ACT). The largest deal of the week, Enact Holdings (ACT) plans...read more